USA flag logo/image

An Official Website of the United States Government

BradyXplore: Bradykinesia Feature Extraction System

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
94066
Program Year/Program:
2009 / SBIR
Agency Tracking Number:
NS065554
Solicitation Year:
N/A
Solicitation Topic Code:
N/A
Solicitation Number:
N/A
Small Business Information
CLEVELAND MEDICAL DEVICES, INC.
4415 EUCLID AVE CLEVELAND, OH 44103
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 2009
Title: BradyXplore: Bradykinesia Feature Extraction System
Agency: HHS
Contract: 1R43NS065554-01A1
Award Amount: $540,680.00
 

Abstract:

DESCRIPTION (provided by applicant): The objective is to design, implement, and clinically assess a portable, user worn, bradykinesia feature extraction system, BradyXplore , for easy integration with CleveMed's existing ParkinSense technology platform. I diopathic Parkinson's disease (PD) and other parkinsonian disorders affect millions of people. Three major symptoms responsible for functional disability and reduced quality of life include tremor, bradykinesia, and rigidity. The current standard in evalua ting symptoms is the Unified Parkinson's Disease Rating Scale (UPDRS), a subjective, qualitative ranking system. While tremor is often the most visible symptom, bradykinesia can be the most impairing to the patient. Objectively quantifying bradykinesia wou ld aid in evaluating treatment protocol efficacy. More specifically, UPDRS scoring instructions for bradykinesia integrates multiple features into a single score that may cause increased inter-rater variability in scores as well as limit the opportunity to explore if particular bradykinesia features are influenced by specific treatment protocols. CleveMed has previously developed a compact wireless system to quantify movement disorder symptoms called ParkinSense . This previously existing technology will se rve as the hardware platform for this proposed program. In a clinical study, this system successfully demonstrated objective quantification of PD motor symptoms. Quantitative variables were processed and applied to algorithms to assess symptom severity. Al gorithm outputs were highly correlated with clinicians' qualitative UPDRS scores for rest, postural, and kinetic tremor. While moderate results were also achieved for bradykinesia, this application addresses optimization of bradykinesia feature extraction including speed, amplitude, and rhythm. The UPDRS uses three tasks to evaluate bradykinesia severity on a 0-4 scale: finger taps; hand opening- closing; and pronation-supination. Patients are instructed to repetitively complete each task as fast and with a s wide an excursion as they can. Clinician scorers are instructed to account for speed, amplitude, fatiguing, hesitations, arrests in movement, and how these variables change over time. Accounting for all of these variables is challenging, even for the mos t experienced movement disorder specialist. It is difficult to gauge weights specific clinicians place on different bradykinesia manifestations. Also, it is unclear if underlying neural mechanisms for different manifestations are the same. Objectively quan tifying specific bradykinesia features should aid in the development of novel DBS therapies for targeting specific bradykinesia manifestations. Furthermore, a portable platform for more continuous monitoring will allow a clinician to capture complex fluctu ation patterns in treatment response. PUBLIC HEALTH RELEVANCE: Parkinson's disease affects more than 1,000,000 people in the United States causing motor symptoms of which one of the most debilitating is bradykinesia (slowed movements). Bradykinesia is curr ently evaluated using a subjective rating scale that gives a single score taking into account speed, amplitude, fatiguing, hesitations, arrests in movement, and how these variables change over time. The proposed BradyXplore bradykinesia feature extraction system will separately quantify specific features of bradykinesia (speed, amplitude, and rhythm), which should aid in the development of novel therapies to target a patient's specific bradykinesia manifestations.

Principal Investigator:

Dustin A. Heldman

Business Contact:

Dustin A. Heldman
hkayyali@clevemed.com
Small Business Information at Submission:

CLEVELAND MEDICAL DEVICES, INC.
4415 EUCLID AVE CLEVELAND, OH 44103

EIN/Tax ID: 341675639
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No